Loading...
Market
How many new competitors will enter the hemophilia treatment market by 2025?
2
Resolution / Starting Odds
No new competitors • 25%
1-2 new competitors • 25%
3-4 new competitors • 25%
5+ new competitors • 25%
Industry news and competitor announcements
Story
European Commission Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A or B
Nov 20, 2024, 09:04 AM
The European Commission has approved Pfizer’s HYMPAVZI™ (marstacimab) for the treatment of adults and adolescents with severe hemophilia A or B without inhibitors. This approval marks a significant advancement in the treatment options available for hemophilia patients, providing a new once-weekly therapy. Pfizer announced that the approval will benefit eligible patients in the European Union, offering a new solution for managing this chronic condition.
View original story
Similar markets
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Yes • 50%
No • 50%
More than 3 competitors • 25%
2 to 3 competitors • 25%
1 competitor • 25%
No new competitors • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%